Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by Accountprinceon Aug 10, 2023 10:39am
217 Views
Post# 35581667

RE:Prowse and Conz

RE:Prowse and Conz Hi MM.  Perhaps the overallotment will cover the costs of issue.  So they may have Cdn $5 million in proceeds.  Given the 90 patient interim milestone (71 done right now) should be within the next 4 months the redacted payment from Baxter could be received.  We aren't privy to that amount but given the current amount of raise could we surmise it'll be sufficient to top them off for the next year?

With Baxter's KidneyCo ready for launch in 2024 would Baxter entertain taking over the Tigris trial if they're happy with the results of the 90 person "exceeding expectations" details?  It would be some market "sizzle" for their new KidneyCo company launch.  It would be like buying a race horse in the final stretch of the Kentucky Derby that is leading by so many lengths that the win is certain.  Incentive is to appear in the Winners Circle at race end with all the fanfare that provides.
<< Previous
Bullboard Posts
Next >>